Influence of long-term treatment with hemin in the development of chronic renal failure in acute intermittent porphyria

2016 ◽  
Vol 146 (8) ◽  
pp. 373-374
Author(s):  
José Salvador García-Morillo ◽  
Aurora González-Estrada ◽  
Santiago Rodriguez-Suarez
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Acute Intermittent Porphyria ◽  
Term Treatment ◽  
Long Term Treatment

Serum 25-Hydroxyvitamin D in Patients with Chronic Renal Failure on Long-Term Treatment with High Doses of Vitamin D2

Nephron ◽  
1980 ◽  
Vol 26 (3) ◽  
pp. 116-120
Author(s):  
Peter Teodor Fröhling ◽  
Franciszek Kokot ◽  
Karl Vetter ◽  
Jadwiga Kuska ◽  
Ingrid Kaschube ◽  
...  
Keyword(s):  
Vitamin D ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Term Treatment ◽  
Hydroxyvitamin D ◽  
Long Term Treatment ◽  
25 Hydroxyvitamin D ◽  
High Doses

scholarly journals Slower Elimination of Tofacitinib in Acute Renal Failure Rat Models: Contribution of Hepatic Metabolism and Renal Excretion

Pharmaceutics ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 714
Author(s):  
Sung Hun Bae ◽  
Sun-Young Chang ◽  
So Hee Kim
Keyword(s):  
Rheumatoid Arthritis ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Hepatic Metabolism ◽  
Term Treatment ◽  
Concentration Time ◽  
Long Term Treatment ◽  
Total Body ◽  
Body Clearance

Tofacitinib is a Jak inhibitor developed as a treatment for rheumatoid arthritis. Tofacitinib is metabolized mainly through hepatic CYP3A1/2, followed by CYP2C11. Rheumatoid arthritis tends to increase renal toxicity due to drugs used for long-term treatment. In this study, pharmacokinetic changes of tofacitinib were evaluated in rats with gentamicin (G-ARF) and cisplatin-induced acute renal failure (C-ARF). The time-averaged total body clearance (CL) of tofacitinib in G-ARF and C-ARF rats after 1-min intravenous infusion of 10 mg/kg was significantly decreased by 37.7 and 62.3%, respectively, compared to in control rats. This seems to be because the time-averaged renal clearance (CLR) was significantly lower by 69.5 and 98.6%, respectively, due to decreased creatinine clearance (CLCR). In addition, the time-averaged nonrenal clearance (CLNR) was also significantly lower by 33.2 and 57.4%, respectively, due to reduction in the hepatic CYP3A1/2 and CYP2C11 subfamily in G-ARF and C-ARF rats. After oral administration of tofacitinib (20 mg/kg) to G-ARF and C-ARF rats, both CLR and CLNR were also significantly decreased. In conclusion, an increase in area under plasma concentration-time curves from time zero to time infinity (AUC) of tofacitinib in G-ARF and C-ARF rats was due to the significantly slower elimination of tofacitinib contributed by slower hepatic metabolism and urinary excretion of the drug.

scholarly journals Oxaliplatin for Metastatic Colon Cancer in a Patient with Renal Failure

2008 ◽  
Vol 2 ◽  
pp. CMO.S412
Author(s):  
Kenji Katsumata ◽  
Tetsuo Sumi ◽  
Tatehiko Wada ◽  
Yasuharu Mori ◽  
Masayuki Hisada ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Renal Failure ◽  
Term Treatment ◽  
Pharmacokinetic Data ◽  
Metastatic Colon Cancer ◽  
Standard Regimen ◽  
Long Term Treatment ◽  
Before And After ◽  
Cecal Cancer

Objective Oxaliplatin, a key part of the standard regimen for colorectal cancer in Western countries, has become available in Japan. In a hemodialysis patient with cecal cancer, we investigated the efficacy, safety, pharmacokinetics, and dialysability of oxaliplatin. Methods A 65-year-old man who had cecal cancer was treated with oxaliplatin (40 mg/m2) and l-leucovorin(l-LV) (200 mg/m2), which were administered simultaneously over 120 min via the side and main arms of a Y-tube, respectively. Then 5-FU (400 mg/m2) was administered rapidly via the side tube, followed by 5-FU (2,000 mg/m2) over 46 hours via the main tube. The patient had chronic renal failure due to diabetic nephropathy and hemodialysis was performed 3 times a week. Blood samples were collected from the dialyzer before and after each hemodialysis session to examine platinum clearance. Results The patient received 3 courses of oxaliplatin before he died of cancer. During hemodialysis, the platinum level fell from 0.32 μg/mL to 0.15 μg/mL. Conclusion Since patients with renal failure have various associated disorders and oxaliplatin has a long half-life, it is necessary to obtain more pharmacokinetic data to investigate its accumulation and dialysability during long-term treatment. Such data will assist in treating the rapidly increasing number of hemodialysis patients with colorectal cancer.

Long-Term Treatment With Minoxidil in Patients With Severe Renal Failure

1980 ◽  
Vol 2 ◽  
pp. S149-155 ◽  
Author(s):  
Rafael Javier ◽  
Francis Dumler ◽  
Jong H. Park ◽  
Diane V. Bok ◽  
Robert W. Riley ◽  
...  
Keyword(s):  
Renal Failure ◽  
Term Treatment ◽  
Severe Renal Failure ◽  
Long Term Treatment

scholarly journals Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy

2021 ◽  
Vol 2021 ◽  
pp. 1-4 ◽  
Author(s):  
Antonio Faieta ◽  
Tavis Dancik
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Interstitial Nephritis ◽  
Acute Interstitial Nephritis ◽  
Term Treatment ◽  
Steroid Dependent ◽  
Long Term Treatment ◽  
Grade 3

A 65-year-old male patient with metastatic CCRCC developed steroid-dependent, grade 3 AIN secondary to nivolumab weeks after its initiation that resulted in 3 hospitalizations with acute renal failure. The patient was started on MM and his AIN was successfully controlled after a 2-year period of follow-up. Refractory renal AIN resulting from PD-1 inhibitor use is rare, and its successful treatment with mofetil mycophenolate with a 2-year follow-up in a patient with metastatic CCRCC has not been reported. This case is important because not only was his renal irAEs controlled but also long-term treatment with MM did not result in progression of metastatic disease.

Sign in / Sign up

Export Citation Format

Share Document